Pharmacists in Brooklyn, CT Accepting Medicare
5 Pharmacists found. Showing 1 - 5
 Erik Reed, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 542 Providence Rd, Brooklyn, CT 06234 Phone: 860-779-0523 Fax: 860-779-0322 |
 Ms. Katelyn Mae Richard, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 542 Providence Rd, Brooklyn, CT 06234 Phone: 860-779-0523 |
Dr. Sarah Nicole Rouslin, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 450 Providence Rd, Brooklyn, CT 06234 Phone: 860-412-5144 Fax: 860-412-5138 |
Lauren Dandeneau, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 542 Providence Rd, Brooklyn, CT 06234 Phone: 860-779-0523 |
Soo Dewolf Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 450 Providence Rd, Brooklyn, CT 06234 Phone: 860-412-5144 Fax: 860-412-5138 |
News Archive
Study finds high rates of drug resistance to urinary tract infections in Bangladesh
Organisms causing urinary tract infections (UTI) are increasingly proving to be ineffective or showing resistance to drugs that are used to kill the germs. This phenomenon has been increasing worldwide, especially to commonly used antimicrobials (drugs) in children.
CICC White Paper identifies several care gaps of atrial fibrillation patients in Ontario
A White Paper released today by the Centre for Innovation in Complex Care (CICC), of the University Health Network (UHN), has identified significant care gaps of atrial fibrillation (AF) patients in Ontario, which contribute to debilitating strokes that could be prevented.
bioTheranostics launches CancerTYPE ID database and KRAS mutational testing
bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.
Enrollment complete in Clovis' CO-101 pivotal study for metastatic pancreatic cancer
Clovis Oncology, Inc. announced today that it has reached the target enrollment in its pivotal LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CO-101 in metastatic pancreatic cancer.
› Verified 6 days ago
Pharmacists
Dentists
Occupational Therapists
Counselors
Clinical Social Workers